

15 July 2026
EMA/145883/2026
Regulatory Science and Innovation Task Force

Agenda — Medicine Shortages SPOC Working Party

Wednesday, 15 July 2026, from 09:30 to 13:30 (CEST), TEAMS

Stand-in Chair: Síofradh McMahon (EMA), Vice-Chair: Ellen McGrath (HPRA)

Item	Topic
1.	Welcome, declaration of interest, adoption of draft agenda
2.	Adoption of draft minutes of the SPOC WP meeting held on 16-17 June 2026
3.	Potential impact of the international situation on the supply of medicinal products for human and veterinary use to the European market:
	• Update on the geopolitical situation • Potential impact of the Super Typhoon Bavi-26 (Inday) on the availability of medicines in EU/EEA
4.	Oral status update on availability of human and veterinary medicines in MSs (only for new emerging information)

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Item	Topic
5.	Critical shortages escalated to the SPOC Working Party:
5.1	Ongoing shortages
	a) Ifosfamide containing medicinal products and cyclophosphamide containing medicinal products, MAH: Baxter
	b) Brevibloc NAP (esmolol), MAH: Baxter
	c) Availability of anti-tuberculosis medicines
	d) Gastrografin NAP and Urografin NAP (sodium amidotrizoate, meglumine amidotrizoate), MAH: Bayer
	e) Albendazole containing medicinal products • Update on current situation in EU/EEA countries • France: Presentation on national situation
5.2	Status update on other critical shortages escalated to the SPOC WP (only comments relating to previously circulated written updates)
	a) Nexobrid CAP (concentrate of proteolytic enzymes enriched in bromelain), MAH: MediWound Germany GmbH
	b) Azactam NAP (aztreonam), MAH: Delbert Pharma
	c) Beriglobin NAP (human normal immunoglobulin), MAH: CSL Behring
	d) Uromitexan NAP (mesna), MAH: Baxter
	e) Medicinal products from MAH Cheplapharm
	f) Insulin containing medicinal products
6.	Impact of nitrosamines impurities on the availability of medicines - update
7.	EC DG SANTE update
8.	Implementation of the New Pharmaceutical Legislation: Provisions related to shortages and security of supply

Item	Topic
9.	Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)-led activities:
	a) Union list of Critical Medicines and Union Long list - update
	b) Feedback from the MSSG WG on Vulnerability Assessment Methodology, including update on Shortage Prevention Plans
10.	European Shortages Monitoring Platform (ESMP) update
11.	AOB
12.	Conclusions and next steps

Next meeting: 15 September (TEAMS) (placeholder 12 August)
